QQQ2.51%

Trending

AVAX5.29%

home Symbol NAGEnews

Exchange: NASDAQ·Updated 07:03 PM EDT

NAGENiagen Bioscience Inc

$3.50

$0.13

(3.86%)

Today

Closed $3.50

$0.00

(0.00%)

After Hours

EarningsAug 5

Mkt Cap$278.76M

Vol952,868.00

Fundamentals

Mkt Cap

$278.76M

52W High

$14.69

52W Low

$3.35

PE Ratio

16.03

Avg. Volume

1.15M

EPS (Annual)

$0.2034

Rev/Employee

$1,106,179.49

Earnings

Aug 05

Info

News

all

press releases

Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times...

Business Wire

More News

Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Companys name...

Business Wire

Niagen Bioscience Announces Participation in Upcoming Investor Conferences

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will...

Business Wire

Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +16.67% and +5.62%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zacks

Niagen Bioscience Keeps Full-Year Sales Forecast Intact As Q1 Revenue, Profit Climbs

Niagen Bioscience reaffirms 2026 sales outlook after first-quarter revenue and profit rose alongside investments in injections and skincare.read more...

Benzinga

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including...

Business Wire

Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the launch of its...

Business Wire

Insider Decision Unfolding At Niagen Bioscience: Robert Fried Exercises Options, Resulting In $46K